新发心力衰竭患者冠状动脉疾病检测的变异性
该研究基于行政索赔数据库分析2004至2019年558,322例新发心衰患者,仅34.8%接受了冠脉疾病检测,9.3%行血运重建;检测率在STICHES发表后无显著变化,且在不同县和心内科医生间存在显著差异。
要点
- 新发心衰患者冠脉疾病检测率低,仅34.8%接受检测。
- 心内科医生共同管理使检测可能性增加(调整OR 5.12)。
- 检测率在地域和医生间差异大,县调整率20%-45%。
核心结论
- 多数新发心衰患者未接受及时冠脉疾病检测,且检测存在地域和医生层面显著差异。
研究设计与样本
- 基于行政索赔数据库(覆盖商业保险和Medicare)的回顾性队列研究,纳入2004至2019年558,322例新发心衰患者。
主要发现
- 34.8%的患者接受了冠脉疾病检测,9.3%接受了血运重建。
- 检测率在STICHES发表后保持平稳,无显著变化。
- 调整后检测率在各县间从20%到45%不等。
- 由心内科医生共同管理的患者检测可能性更高(调整OR 5.12;95%CI 4.98-5.27),但不同心内科医生间差异大(IQR 50.9%-62.4%)。
临床怎么用
- 临床中应关注新发心衰患者的冠脉疾病检测,尤其在地域和医生差异背景下优化检测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary artery disease (CAD) is the most common cause of new-onset heart failure (HF). Although guidelines recommend ischemic evaluation in this population, testing has historically been underutilized. OBJECTIVES: This study aimed to identify contemporary trends in CAD testing for patients with new-onset HF, particularly after publication of the STICHES (Surgical Treatment for Ischemic Heart Failure Extension Study), and to characterize geographic and clinician-level variability in testing patterns. METHODS: We determined the proportion of patients with incident HF who received CAD testing from 2004 to 2019 using an administrative claims database covering commercial insurance and Medicare. We identified demographic and clinical predictors of CAD testing during the 90 days before and after initial diagnosis. Patients were grouped by their county of residence to assess national variation. Patients were then linked to their primary care physician and/or cardiologist to evaluate variation across clinicians. RESULTS: Among 558,322 patients with new-onset HF, 34.8% underwent CAD testing and 9.3% underwent revascularization. After multivariable adjustment, patients who underwent CAD testing were more likely to be younger, male, diagnosed in an acute care setting, and have systolic dysfunction or recent cardiogenic shock. Incidence of CAD testing remained flat without significant change post-STICHES. Covariate-adjusted testing rates varied from 20% to 45% across counties. The likelihood of testing was higher among patients co-managed by a cardiologist (adjusted OR: 5.12; 95% CI: 4.98-5.27) but varied substantially across cardiologists (IQR: 50.9%-62.4%). CONCLUSIONS: Most patients with new-onset HF across inpatient and outpatient settings did not receive timely testing for CAD. Substantial variability in testing persists across regions and clinicians.
引用
- Zheng, Heidenreich, Kohsaka, et al. Variability in Coronary Artery Disease Testing for Patients With New-Onset Heart Failure. J Am Coll Cardiol. 2022. PMID: 35241218. doi:10.1016/j.jacc.2021.11.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。